Abstract
Purpose: To develop a sensitive and validated reverse phase-high performance liquid chromatographic (RP-HPLC) method for quantification of olanzapine in micro-sample of rat plasma using UV detection.Methods: A single oral dose of olanzapine (7 mg/kg) was given to overnight fasted rats (n = 6). Rat plasma samples containing the drug were extracted by liquid-liquid extraction using a combination of dichloromethane: n-hexane (80:20). A reverse phase chromatographic column C18 hypersil-BDS was used for chromatographic separation with a mobile phase consisting of 50 mM phosphate buffer pH 5.5, acetonitrile and methanol (50:30:20, v/v/v) pumped at a flow rate of 1.2 ml/min. Olanzapine was measured using ultraviolet (UV) detection at 214 nm. The method was validated for precision and accuracy.Results: Separation of compounds of interest was not affected by endogenous interference. Good linearity within the concentration range of 1 - 500 ng/ml in rat plasma was obtained with coefficient of regression (r2) of 0.9986. Liquid-liquid extraction produced comparable recovery to solid phase extraction. Retention time of olanzapine and internal standard (fluoxetine) was 5.0 and 13.4 min, respectively. Lowest limit of quantification (LLOQ) was 1 ng/ml while inter-day and intra-day precision was < 12.5 and 5.1 %, respectively. Accuracy of the method was between 94 and 105 % and the variation of results between two analysts was not significant (p = 0.626). Mean maximum plasma concentration (Cmax) of olanzapine was 412.7 ng/ml, time to attain maximum plasma concentration (tmax) was 1 h and half life (t½) was 2.54 h.Conclusion: The proposed method has been successfully validated for precision and accuracy that are within the limits of U.S. Food and Drug Administration (FDA)’s guidance for bioanalyitcal assay validation. The method was successfully applied to preclinical pharmacokinetic analysis of olanzapine in rats.Keywords: Olanzapine, Antipsychotic, Pharmacokinetics, Rat, Plasma, Bioanalytical assay Olanzapine, Antipsychotic, Pharmacokinetics, Rat, Plasma, Bioanalytical assay
Highlights
Olanzapine is a thienobenzodiazipine derivative which is an atypical antipsychotic effectively used in the treatment of schizophrenia and bipolar disorders [1,2]
Chromatograms of blank plasma and drug free plasma spiked with 100 ng of olanzapine and 500 ng of fluoxetine (I.S) is illustrated in (Figure 2)
Standard curve was established by taking ratio of peak area of olanzapine and that of fluoxetine (I.S) as a function of olanzapine plasma concentration
Summary
Olanzapine is a thienobenzodiazipine derivative which is an atypical antipsychotic effectively used in the treatment of schizophrenia and bipolar disorders [1,2]. Olanzapine has shown to have affinity with dopamine D1 and D2, muscarinic and serotonin 5HT2 receptors [3]. Plasma concentration of olanzapine has a correlation with its clinical effects and shown to have individual variability in its pharmacokinetics [4,5]. Many drug interactions with olanzapine have shown to change the pharmacokinetics of olanzapine [6]. The mobile phase consisted of 50 % phosphate buffer of 50mM maintained at pH 5.5- Acetonitrile-methanol (50:30:20) (v/v/v) which was run at the flow rate of 1.2 ml/min. Mobile phase was filtered through 0.45 μm membrane by vacuum filtration and degassed by ultrasonicator prior to use. Detection of olanzapine was carried out on an ultraviolet detector at 214 nm
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
